Form 4: CFO Ryan Lake Disposes Shares for Tax Withholding

LifeCore Biomedical CFO Ryan Lake disposed of 22,932 common shares at $7.71 each to cover tax obligations related to RSU vesting.

Summary

• Ryan Lake, Chief Financial Officer of LifeCore Biomedical, Inc. (LFCR), disposed of 22,932 shares of common stock.
• The transaction occurred on September 3, 2025, at a price of $7.71 per share.
• This disposition was made to satisfy tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• Following this transaction, Mr. Lake beneficially owns 336,691 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine tax withholding related to RSU vesting, which is a neutral event and does not indicate positive or negative sentiment towards the company's performance or future prospects.

Future Outlook

NA

Industry Context

This is a routine insider transaction for tax withholding purposes, common across all industries when executive compensation includes Restricted Stock Units (RSUs) that vest. It does not reflect a strategic move or industry trend.

Related Party Transactions

• The transaction involves the disposition of shares to the issuer (LifeCore Biomedical, Inc.) to satisfy tax withholding obligations, which is a common type of related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax-related disposition, not a discretionary sale. It slightly increases the public float if the shares were previously restricted, but the number is small relative to total outstanding shares.
• Management: The CFO's beneficial ownership remains substantial, indicating continued alignment with shareholder interests.

Key Dates

Recommendation

This Form 4 filing details a routine tax-related disposition of shares by the CFO upon RSU vesting. Such transactions are common and generally do not reflect a change in the executive's outlook on the company's fundamentals or future prospects. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based on existing company analysis.

Keywords

LifeCore Biomedical, LFCR, Ryan Lake, CFO, Form 4, insider transaction, share disposition, tax withholding, RSU vesting, common stock